TCR-based T-cell therapy (Leiden University Medical Center/Kite Pharma)

N/A

Report date: 2025/02/01 20:00:06

Base Information

Drug NameTCR-based T-cell therapy (Leiden University Medical Center/Kite Pharma)
Drug Alias NameAnti-HPV-16 TCR T-cell therapy (Leiden University Medical Center/Kite Pharma)
ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapyBiologics > Protein drugs > Recombinant protein
Mechanisms of ActionHuman leukocyte antigen modulators
TargetsHuman leukocyte antigen
Therapy Area/IndicationsSolid tumours
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryEuropeNetherlands
CombinationsNo
Global Highest StatusPending (Preclinical)
Highest Status in ChinaN/A
Originator CompaniesLeiden University Medical Center
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLeiden University Medical CenterKite Pharma Inc
Active IndicationsN/A
Inactive IndicationsSolid tumours

Other Information

ATC CodeN/A
Related LinksN/A